BackgroundRecently high-throughput technologies have been massively used alongside clinical tests to study various types of cancer. Data generated in such large-scale studies are heterogeneous, of different types and formats. With lack of effective integration strategies novel models are necessary for efficient and operative data integration, where both clinical and molecular information can be effectively joined for storage, access and ease of use. Such models, combined with machine learning methods for accurate prediction of survival time in cancer studies, can yield novel insights into disease development and lead to precise personalized therapies.ResultsWe developed an approach for intelligent data integration of two cancer datasets (breast cancer and neuroblastoma) − provided in the CAMDA 2018 ‘Cancer Data Integration Challenge’, and compared models for prediction of survival time. We developed a novel semantic network-based data integration framework that utilizes NoSQL databases, where we combined clinical and expression profile data, using both raw data records and external knowledge sources. Utilizing the integrated data we introduced Tumor Integrated Clinical Feature (TICF) − a new feature for accurate prediction of patient survival time. Finally, we applied and validated several machine learning models for survival time prediction.ConclusionWe developed a framework for semantic integration of clinical and omics data that can borrow information across multiple cancer studies. By linking data with external domain knowledge sources our approach facilitates enrichment of the studied data by discovery of internal relations. The proposed and validated machine learning models for survival time prediction yielded accurate results.ReviewersThis article was reviewed by Eran Elhaik, Wenzhong Xiao and Carlos Loucera.

The application of machine learning models for prediction and prognosis of disease development has become an irrevocable part of cancer studies aimed at improving the subsequent therapy and management of patients. The application of machine learning models for accurate prediction of survival time in breast cancer on the basis of clinical data is the main objective of the presented study. The paper discusses an approach to the problem in which the main factor used to predict survival time is the originally developed tumor-integrated clinical feature, which combines tumor stage, tumor size, and age at diagnosis. Two datasets from corresponding breast cancer studies are united by applying a data integration approach based on horizontal and vertical integration by using proper document-oriented and graph databases which show good performance and no data losses. Aside from data normalization and classification, the applied machine learning methods provide promising results in terms of accuracy of survival time prediction. The analysis of our experiments shows an advantage of the linear Support Vector Regression, Lasso regression, Kernel Ridge regression, K-neighborhood regression, and Decision Tree regression—these models achieve most accurate survival prognosis results. The cross-validation for accuracy demonstrates best performance of the same models on the studied breast cancer data. As a support for the proposed approach, a Python-based workflow has been developed and the plans for its further improvement are finally discussed in the paper.

The steady elaboration of the Metagenomic and Metadesign of Subways and Urban Biomes (MetaSUB) international consortium project raises important new questions about the origin, variation, and antimicrobial resistance of the collected samples. CAMDA (Critical Assessment of Massive Data Analysis, http://camda.info/) forum organizes annual challenges where different bioinformatics and statistical approaches are tested on samples collected around the world for bacterial classification and prediction of geographical origin. This work proposes a method which not only predicts the locations of unknown samples, but also estimates the relative risk of antimicrobial resistance through spatial modeling. We introduce a new component in the standard analysis as we apply a Bayesian spatial convolution model which accounts for spatial structure of the data as defined by the longitude and latitude of the samples and assess the relative risk of antimicrobial resistance taxa across regions which is relevant to public health. We can then use the estimated relative risk as a new measure for antimicrobial resistance. We also compare the performance of several machine learning methods, such as Gradient Boosting Machine, Random Forest, and Neural Network to predict the geographical origin of the mystery samples. All three methods show consistent results with some superiority of Random Forest classifier. In our future work we can consider a broader class of spatial models and incorporate covariates related to the environment and climate profiles of the samples to achieve more reliable estimation of the relative risk related to antimicrobial resistance.

No abstract

No abstract